REPORTS FULL-YEAR ADJUSTED EPS OF $3.32, UP 5.7 PERCENT; GAAP EPS $1.10- DELIVERS FOURTH-QUARTER ADJUSTED REVENUE OF $5.371 BILLION, UP 8.9 PERCENT OVER FOURTH-QUARTER 2013 (UP 5.1 PERCENT ON A REPORTED BASIS); GAAP REVENUE $5.452 BILLION- REVENUE GROWTH IN THE QUARTER REFLECTS 14.4 PERCENT GLOBAL OPERATIONAL SALES GROWTH FROM HUMIRA (UP 10.6 PERCENT ON A REPORTED BASIS) AND STRONG GROWTH FROM OTHER KEY PRODUCTS- DELIVERS ADJUSTED GROSS MARGIN IMPROVEMENT OF 410 BASIS POINTS IN THE FOURTH QUARTER- REPORTS FOURTH-QUARTER ADJUSTED EPS OF $0.89, UP 8.5 PERCENT; GAAP EPS ($0.51)- LAUNCHES INTERFERON-FREE HCV REGIMEN FOLLOWING APPROVAL IN UNITED STATES, EUROPE AND CANADA- CONFIRMS 2015 ADJUSTED EPS GUIDANCE RANGE, REFLECTING INDUSTRY-LEADING GROWTH VERSUS THE PRIOR YEAR
Global HUMIRA sales increased 10.6 percent, or 14.4 percent on an operational basis, excluding the impact of foreign exchange rate fluctuations.
Via
Krishan Maggon
mAbs Vol & Issue 3
pages 605-619
Publishing models and article dates explainedReceived: 11 Nov 2014Accepted: 1 Mar 2015Accepted author version posted online: 12 Mar 2015